AlloVir, Inc.

NasdaqCM:ALVR Rapport sur les actions

Capitalisation boursière : US$84.3m

AlloVir Croissance future

Future contrôle des critères 0/6

AlloVir devrait augmenter ses bénéfices de 24.3% par an. Le BPA devrait augmenter de 20.6% par an.

Informations clés

24.3%

Taux de croissance des bénéfices

20.6%

Taux de croissance du BPA

Biotechs croissance des bénéfices26.7%
Taux de croissance des recettesn/a
Rendement futur des capitaux propresn/a
Couverture par les analystes

Low

Dernière mise à jour12 Nov 2024

Mises à jour récentes de la croissance future

Recent updates

AlloVir (NASDAQ:ALVR) Will Have To Spend Its Cash Wisely

Oct 29
AlloVir (NASDAQ:ALVR) Will Have To Spend Its Cash Wisely

Here's Why AlloVir (NASDAQ:ALVR) Must Use Its Cash Wisely

Jul 13
Here's Why AlloVir (NASDAQ:ALVR) Must Use Its Cash Wisely

We Think AlloVir (NASDAQ:ALVR) Needs To Drive Business Growth Carefully

Feb 09
We Think AlloVir (NASDAQ:ALVR) Needs To Drive Business Growth Carefully

Here's Why We're Watching AlloVir's (NASDAQ:ALVR) Cash Burn Situation

Oct 03
Here's Why We're Watching AlloVir's (NASDAQ:ALVR) Cash Burn Situation

Here's Why We're Watching AlloVir's (NASDAQ:ALVR) Cash Burn Situation

Jun 23
Here's Why We're Watching AlloVir's (NASDAQ:ALVR) Cash Burn Situation

Is AlloVir (NASDAQ:ALVR) In A Good Position To Deliver On Growth Plans?

Mar 02
Is AlloVir (NASDAQ:ALVR) In A Good Position To Deliver On Growth Plans?

Is AlloVir (NASDAQ:ALVR) In A Good Position To Deliver On Growth Plans?

Nov 11
Is AlloVir (NASDAQ:ALVR) In A Good Position To Deliver On Growth Plans?

AlloVir GAAP EPS of $0.69 beats by $1.42

Aug 04

AlloVir stock surges on $126.6M securities offering

Jul 27

Is AlloVir (NASDAQ:ALVR) In A Good Position To Invest In Growth?

Jul 27
Is AlloVir (NASDAQ:ALVR) In A Good Position To Invest In Growth?

Here's Why We're Not Too Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Situation

Mar 21
Here's Why We're Not Too Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Situation

AlloVir: A Comparative Study Of Its Manufacturing Process

Feb 07

We're Not Very Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Rate

Nov 02
We're Not Very Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Rate

AlloVir, Inc.: Creating Solutions For Stem Cell Transplant Issues

Oct 02

AlloVir, Inc.'s (NASDAQ:ALVR) Intrinsic Value Is Potentially 24% Below Its Share Price

Aug 06
AlloVir, Inc.'s (NASDAQ:ALVR) Intrinsic Value Is Potentially 24% Below Its Share Price

We Think AlloVir (NASDAQ:ALVR) Can Afford To Drive Business Growth

Jul 01
We Think AlloVir (NASDAQ:ALVR) Can Afford To Drive Business Growth

AlloVir EPS misses by $0.08

May 06

AlloVir (NASDAQ:ALVR) Is In A Good Position To Deliver On Growth Plans

Apr 01
AlloVir (NASDAQ:ALVR) Is In A Good Position To Deliver On Growth Plans

This Insider Has Just Sold Shares In AlloVir, Inc. (NASDAQ:ALVR)

Feb 07
This Insider Has Just Sold Shares In AlloVir, Inc. (NASDAQ:ALVR)

Is AlloVir, Inc.'s (NASDAQ:ALVR) Shareholder Ownership Skewed Towards Insiders?

Jan 08
Is AlloVir, Inc.'s (NASDAQ:ALVR) Shareholder Ownership Skewed Towards Insiders?

FDA clears AlloVir's ALVR106 application in respiratory viruses

Dec 17

Allovir's COVID-19 therapy saw anti-viral activity in pre-clinical data

Dec 07

We Think AlloVir (NASDAQ:ALVR) Can Afford To Drive Business Growth

Dec 04
We Think AlloVir (NASDAQ:ALVR) Can Afford To Drive Business Growth

AlloVir EPS misses by $0.28

Nov 10

Prévisions de croissance des bénéfices et des revenus

NasdaqCM:ALVR - Estimations futures des analystes et données financières antérieures (USD Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
12/31/2026N/A-54N/AN/A1
12/31/2025N/A-79N/AN/A1
12/31/2024N/AN/AN/AN/A1
6/30/2024N/A-140-121-121N/A
3/31/2024N/A-180-137-137N/A
12/31/2023N/A-190-124-124N/A
9/30/2023N/A-169-125-125N/A
6/30/2023N/A-167-126-126N/A
3/31/2023N/A-166-128-128N/A
12/31/2022N/A-169-142-142N/A
9/30/2022N/A-189-138-139N/A
6/30/2022N/A-192-140-140N/A
3/31/2022N/A-185-134-134N/A
12/31/2021N/A-172-106-106N/A
9/30/2021N/A-139-100-99N/A
6/30/2021N/A-117-82-81N/A
3/31/2021N/A-91-70-69N/A
12/31/2020N/A-70-61-61N/A
9/30/2020N/A-53-49-49N/A
6/30/2020N/A-37-37-37N/A
3/31/2020N/A-31-29-29N/A
12/31/20190-24-20-20N/A
12/31/20181-822N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: ALVR devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: ALVR devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: ALVR devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Données insuffisantes pour déterminer si les revenus de ALVR devraient croître plus rapidement que le marché US.

Croissance élevée des revenus: ALVR ne devrait pas générer de revenus l'année prochaine.


Prévisions de croissance du bénéfice par action


Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de ALVR devrait être élevé dans 3 ans


Découvrir les entreprises en croissance